Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension

Not Applicable

Withdrawn

• Conditions: Chronic Obstructive Lung Disease
• Interventions: Drug: Tadalafil

• Registration Number: NCT00506701
• Lead Sponsor: Herlev Hospital

Brief Summary

Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.

Detailed Description

Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.

Study Timeline

• Status Verified: 2007-07
• Study First Submitted: 2007-07-23
• Study First Submitted QC: 2007-07-23
• Study First Posted: 2007-07-25
• Study Start: 2008-02
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Last Update Submitted: 2015-03-17
• Last Update Posted: 2015-03-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Clinical diagnosis of Chronic obstructive lung disease

Exclusion Criteria

• Patients with asthma

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Tadalafil treatment 40 mg	Tadalafil	-

Primary Outcome Measures

Name	Time	Method
Change in 6 min. walking test	6 months

Trial Locations

Locations (1)

Herlev University Hospital; 🇩🇰 Herlev, Denmark